98%
921
2 minutes
20
Background: Olfactory dysfunction is among the earliest non-motor symptoms of Parkinson's disease (PD). As the foremost pathological hallmark, α-synuclein initiates the pathology in the olfactory pathway at the early stage of PD, particularly in the olfactory epithelium (OE) and olfactory bulb (OB). However, the local neural microcircuit mechanisms underlying olfactory dysfunction between OE and OB in early PD remain unknown.
Results: We observed that odor detection and discrimination were impaired in 6-month-old SNCA-A53T mice, while their motor ability remained unaffected. It was confirmed that α-synuclein increased and accumulated in OB but not in OE. Notably, the hyperactivity of mitral/tufted cells and the excitation/inhibition imbalance in OB were found in 6-month-old SNCA-A53T mice, which was attributed to the impaired GABAergic transmission and aberrant expression of GABA transporter 1 and vesicular GABA transporter in OB. We further showed that tiagabine, a potent and selective GABA reuptake inhibitor, could reverse the impaired olfactory function and GABAergic signaling in OB of SNCA-A53T mice.
Conclusions: Taken together, our findings demonstrate potential synaptic mechanisms of local neural microcircuit underlying olfactory dysfunction at the early stage of PD. These results highlight the critical role of aberrant GABAergic signaling of OB in early diagnosis and provide a potential therapeutic strategy for early-stage PD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239587 | PMC |
http://dx.doi.org/10.1186/s13578-023-01049-9 | DOI Listing |
Alcohol Clin Exp Res (Hoboken)
September 2025
Department of Neuroscience and Experimental Therapeutics, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Background: Prenatal alcohol exposure (PAE) causes fetal alcohol spectrum disorder (FASD) and is associated with various cognitive and sensory impairments, including olfactory dysfunction. While both genetic and environmental factors contribute to olfactory dysfunction, PAE is considered a significant factor affecting brain development, including the olfactory system. In this study, we investigated the impact of PAE on the developing olfactory bulb (OB), specifically focusing on OB RGCs-radial glial cells that give rise to OB projection neurons.
View Article and Find Full Text PDFCell Genom
September 2025
Department of Genetics, Stanford University, Stanford, CA, USA. Electronic address:
Non-olfactory G-protein-coupled receptors (GPCRs) regulate vital physiological functions and are targets for ∼34% of US Food and Drug Administration (FDA)-approved drugs. While small-molecule-activated GPCRs are well studied, there is growing interest in peptide GPCRs, particularly the melanocortin-4 receptor (MC4R), a key regulator of energy balance and appetite. Activation of MC4R by β-melanocyte-stimulating hormone (β-MSH) reduces food intake, and pathway dysfunction leads to obesity.
View Article and Find Full Text PDFPsychogeriatrics
September 2025
Department of Psychiatry, The 4th People's Hospital of Ziyang, Ziyang Psychosis Hospital, Ziyang, China.
Background: Olfactory training (OT) has been proposed as a non-pharmacological intervention to improve cognitive functions and depressive symptomatology, but evidence remains fragmented.
Methods: In this study, we conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing OT versus control in middle-aged and elderly adults. Four databases (PubMed, Cochrane Library, Web of Science, Embase) were systematically searched from database inception through June 2025.
Diabetes Obes Metab
September 2025
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, Denmark.
Background: Taste and smell disorders are more common in individuals with diabetes, particularly among those with low insulin sensitivity or central obesity. These disorders may affect glycaemic control by altering dietary habits. This study aimed to investigate self-reported taste and smell dysfunction in individuals with diabetes and explore associations with clinical and behavioural factors.
View Article and Find Full Text PDFMov Disord Clin Pract
September 2025
Department of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Background: Early identification of pathological α-synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease-modifying treatments.
Objectives: We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory dysfunction (iOD).
Methods: In this cross-sectional, case-control study, we included iOD participants and normosmic healthy controls (HC) aged 55 to 75 years without diagnoses of dementia with Lewy bodies, Parkinson's disease (PD), or other major neurological disorders.